This human clinical study investigated how the glycyl-L-histidyl-L-lysine-Cu(2+) (GHK-Cu) tripeptide complex affects lung inflammation and fibrosis in silicosis by examining its interaction with peroxiredoxin 6. The researchers found that GHK-Cu attenuated both inflammatory and fibrotic responses in silicosis through a mechanism involving peroxiredoxin 6 as a molecular target. This evidence comes from human clinical research, representing the highest level of evidence for translational application to silicosis management.